News
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...
TipRanks on MSN9h
CureVac sees cash runway into 2028
Cash and cash equivalents amounted to EUR 392.7 million at the end of June 2025, decreasing from EUR 481.7 million at the end of 2024. In the ...
TipRanks on MSN9h
CureVac reports Q2 revenue EUR 1.2M vs. EUR 14.4M last year
By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...
Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...
New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...
Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback